References
- Stein H, Foss HD, Dürkop H, et al. CD30(+) anaplastic large cell lymphoma:a review of its histopathologic, genetic, and clinical features. Blood 2000;96:3681–3695.
- Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999;93:2697–2706.
- Pai SA, Naresh KN, Patil PU. Systemic anaplastic large cell lymphoma presenting as a bladder neoplasm. Leuk Lymphoma 2004;45:841–843.
- Murphy AJ, O’Neill P, O’Brien F, et al. Anaplastic large cell lymphoma: a unique presentation with urinary bladder involvement: a case report. Int J Surg Pathol 2005;13:369–373.
- Gómez-Román JJ, Cobo ML, Val-Bernal JF. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma presenting as a bladder neoplasm. Pathol Int 2008;58:249–252.
- Blick C, Abdelhadi S, Bailey D, et al. Anaplastic, T-cell, non-Hodgkin's Lymphoma presenting with haematuria. Sci World J 2008;8:342–345.
- Le Deley MC, Rosolen A, Williams DM, et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol 2010;28:3987–3993.
- Ito M, Hiramatsu H, Kobayashi K, et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002;100:3175–3182.
- Pfeifer W, Levi E, Petrogiannis-Haliotis T, et al. A murine xenograft model for human CD30 + anaplastic large cell lymphomacell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1). Am J Pathol 1999;155:1353–1359.
- Zhang M, Yao Z, Zhang Z, et al. Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors. Blood 2006;108:705–710.